How much does Jiatailai (Sacituzumab Tirumotecan for Injection) Cost& price without insurance in China?
Jiatailai® is the domestic commercial brand name of Sacituzumab Tirumotecan for Injection, a Trop-2 targeted antibody-drug conjugate (ADC) independently developed by Kelun-Biotech. It consists of a humanized anti-Trop-2 monoclonal antibody conjugated with topoisomerase I inhibitor tirumotecan via a cleavable linker. The antibody specifically binds to Trop-2 overexpressed on tumor cells, releasing cytotoxic payload inside tumor cells to induce DNA damage and tumor cell apoptosis, with low off-target toxicity to normal tissues.
Main Indications
Treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in adult patients who have received at least two prior systemic therapies, with at least one regimen for metastatic disease.
Treatment of unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer after failure of prior endocrine therapy and chemotherapy.
Monotherapy for locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment.
Clinical Research
Multiple pivotal Phase III clinical trials supported all marketing indications of sacituzumab tirumotecan:
OptiTROP-Breast01: In pre-treated metastatic triple-negative breast cancer, sacituzumab tirumotecan achieved an objective response rate (ORR) of 43.8%, significantly prolonging median progression-free survival compared with conventional chemotherapy.
OptiTROP-Breast02: The Phase III trial confirmed clinical benefit in HR-positive, HER2-negative metastatic breast cancer patients with prior treatment failure, showing durable tumor regression and controllable safety profile.
OptiTROP-Lung01: For EGFR-TKI resistant EGFR-mutated NSCLC, sacituzumab tirumotecan reduced the risk of disease progression or death by 40% versus standard chemotherapy, with prominent overall survival improvement and low incidence of interstitial lung disease.
A series of Phase II exploratory studies further validated its anti-tumor activity in gynecologic malignancies and combination regimens with immune checkpoint inhibitors.
Common Side Effects
Common mild adverse reactions: Neutropenia, anemia, oral mucositis, fatigue, alopecia, nausea, vomiting and ocular surface disorders;
Laboratory abnormalities: Decreased neutrophil count, reduced hemoglobin, elevated liver transaminases;
Severe but uncommon risks: Severe grade 3–4 myelosuppression complicated by infection, severe ocular toxicity, grade 3/4 mucositis and infusion-related hypersensitivity reactions.
Approval Status in China
Jiatailai® (Sacituzumab Tirumotecan for Injection, 200mg per vial, research code SKB264/MK-2870) obtained its first conditional marketing approval in China in 2024, with supplementary indications for HR+/HER2- breast cancer and EGFR-mutated NSCLC approved in early 2026. It is a fully domestically developed Trop-2 ADC prescription anti-tumor biologic agent.
Buy Jiatailai (Sacituzumab Tirumotecan for Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
